Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV; VITAL-1 study team. Pawlotsky JM, et al. Hepatology. 2015 Oct;62(4):1013-23. doi: 10.1002/hep.27960. Epub 2015 Aug 10. Hepatology. 2015. PMID: 26118427 Clinical Trial.
Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.
Vermehren J, Maasoumy B, Maan R, Cloherty G, Berkowski C, Feld JJ, Cornberg M, Pawlotsky JM, Zeuzem S, Manns MP, Sarrazin C, Wedemeyer H. Vermehren J, et al. Among authors: pawlotsky jm. Clin Infect Dis. 2016 May 15;62(10):1228-1234. doi: 10.1093/cid/ciw061. Epub 2016 Feb 9. Clin Infect Dis. 2016. PMID: 26908802
Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. de Lédinghen V, et al. Among authors: pawlotsky jm. Clin Infect Dis. 2018 Mar 19;66(7):1013-1018. doi: 10.1093/cid/cix916. Clin Infect Dis. 2018. PMID: 29077864 Free article. Clinical Trial.
Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.
Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C. Talal AH, et al. Among authors: pawlotsky jm. J Infect Dis. 2018 Jan 17;217(3):474-482. doi: 10.1093/infdis/jix495. J Infect Dis. 2018. PMID: 29228392 Free PMC article. Clinical Trial.
Characterization of the Anti-Hepatitis C Virus Activity of New Nonpeptidic Small-Molecule Cyclophilin Inhibitors with the Potential for Broad Anti-Flaviviridae Activity.
Nevers Q, Ruiz I, Ahnou N, Donati F, Brillet R, Softic L, Chazal M, Jouvenet N, Fourati S, Baudesson C, Bruscella P, Gelin M, Guichou JF, Pawlotsky JM, Ahmed-Belkacem A. Nevers Q, et al. Among authors: pawlotsky jm. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00126-18. doi: 10.1128/AAC.00126-18. Print 2018 Jul. Antimicrob Agents Chemother. 2018. PMID: 29760125 Free PMC article.
Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. Softic L, et al. Among authors: pawlotsky jm. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00876-20. doi: 10.1128/AAC.00876-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32376613 Free PMC article.
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.
Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel TA, Lescure FX, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky JM, Michel M, Perrodeau E, Carlier N, Roche N, de Lastours V, Ourghanlian C, Kerneis S, Ménager P, Mouthon L, Audureau E, Ravaud P, Godeau B, Gallien S, Costedoat-Chalumeau N. Mahévas M, et al. Among authors: pawlotsky jm. BMJ. 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844. BMJ. 2020. PMID: 32409486 Free PMC article.
Performance of 30 commercial SARS-CoV-2 serology assays in testing symptomatic COVID-19 patients.
Vauloup-Fellous C, Maylin S, Périllaud-Dubois C, Brichler S, Alloui C, Gordien E, Rameix-Welti MA, Gault E, Moreau F, Fourati S, Challine D, Pawlotsky JM, Houhou-Fidouh N, Damond F, Mackiewicz V, Charpentier C, Méritet JF, Rozenberg F, Podglajen I, Marot S, Petit H, Burrel S, Akhavan S, Leruez-Ville M, Avettand-Fenoel V, Fourgeaud J, Guilleminot T, Gardiennet E, Bonacorsi S, Carol A, Carcelain G, Villemonteix J, Boukli N, Gozlan J, Morand-Joubert L, Legoff J, Delaugerre C, Chaix ML, Roque-Afonso AM, Dortet L, Naas T, Ronat JB, Lepape S, Marcelin AG, Descamps D. Vauloup-Fellous C, et al. Among authors: pawlotsky jm. Eur J Clin Microbiol Infect Dis. 2021 Oct;40(10):2235-2241. doi: 10.1007/s10096-021-04232-3. Epub 2021 Mar 29. Eur J Clin Microbiol Infect Dis. 2021. PMID: 33782783 Free PMC article.
506 results